Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Blood (2021) 138 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2021-150904

Published: 2021

Journal Articles

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139291

Published: 2020

Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Blood (2019) 134 (Supplement_1): 2998.

https://doi.org/10.1182/blood-2019-129047

Published: 2019

Journal Articles

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Blood (2017) 130 (Supplement 1): 323.

https://doi.org/10.1182/blood.V130.Suppl_1.323.323

Published: 2017

Journal Articles

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, MD PhD, Christian Récher, MDPhD, Julie Lejeune, Aspasia Stamatoullas, MD, Marie Sebert, MD, Jacques Delaunay, MD, Benedicte Samey, Krimo Bouabdallah, MD, Thorsten Braun, MD PhD, Norbert Vey, Sophie Park, MD PhD, Benoit de Renzis, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2892.

https://doi.org/10.1182/blood.V126.23.2892.2892

Published: 2015

Journal Articles

Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM)

Marie Sebert, MD, Aspasia Stamatoullas, MD, Thorsten Braun, MD PhD, Jacques Delaunay, MD, Benoît de Renzis, Ramzi Jeddi, MD, Balkis Meddeb, Mathilde Hunault Berger, Benedicte Samey, Fatiha Chermat, Sylvie Chevret, Cendrine Chaffaut, Pierre Fenaux, MD PhD, Lionel Ades, MD PhD

Blood (2015) 126 (23): 2884.

https://doi.org/10.1182/blood.V126.23.2884.2884

Published: 2015

Journal Articles

Long Term Efficacy and Tolerance of Pegylated Interferon Alpha Therapy for Patients with High Risk Essential Thrombocythemia: An Observational Study of the French Intergroup of Myeloproliferative Disorders (FIM)

Lydia Roy, MD, Jean Christophe Ianotto, MD, Joelle Guilhot, PhD, Christian Récher, MDPhD, Laurence Legros, MD PhD, Dana Ranta, MD, Emmanuel Raffoux, MD, Pascale Cony Makhoul, Emmanuel Gyan, MD PhD, Benoit de Renzis, MD, Françoise Boyer, MD, Thierry Muron, MD, Franck Emmanuel Nicolini, MD PhD, Kamel Laribi, MD, Jean-Jacques Kiladjian, MD PhD, Stephane Giraudier, MD PhD

Blood (2014) 124 (21): 1845.

https://doi.org/10.1182/blood.V124.21.1845.1845

Published: 2014

Journal Articles

A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Christian Recher, MD PhD, Aspasia Stamatoullas, Krimo Bouabdallah, MD, Jacques Delaunay, MD, Francois Dreyfus, MD, Norbert Vey, MD PhD, Benoit de Renzis, Emmanuel Raffoux, Françoise Isnard, MD, Benedicte Samey, Cendrine Chaffaut, Sylvie Chevret, Pierre Fenaux, MD, PhD

Blood (2013) 122 (21): 2750.

https://doi.org/10.1182/blood.V122.21.2750.2750

Published: 2013

Journal Articles

Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies

Lionel Ades, MD, PhD, Benoit de Renzis, Ramzi Jeddi, MD, Jacques Delaunay, MD, Thorsten Braun, Mathilde Hunault Berger, MD, PhD, Aspasia Stamatoullas, Laurence Sanhes, MD, Benedicte Samey, Fatiha Chermat, Baklis Meddeb, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 1720.

https://doi.org/10.1182/blood.V120.21.1720.1720

Published: 2012

Journal Articles

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

Cecile Bally, Raphael Itzykson, MD, Berangere Gruson, MD, Dreyfus Francois, Virginie Siguret, Anne-Laure Taksin, Benoit de Renzis, Laurence Legros, Xavier Thomas, MD, PhD, Krimo Bouabdallah, MD, Pascal Chaibi, MD, Charikleia Kelaidi, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2011) 118 (21): 2786.

https://doi.org/10.1182/blood.V118.21.2786.2786

Published: 2011

Journal Articles

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial

Blood (2011) 118 (14): 3824–3831.

https://doi.org/10.1182/blood-2011-05-352039

Published: 2011

Includes: Supplemental data

Journal Articles

Pegylated Interferon Alpha-2a Therapy for Patients with High Risk Essential Thrombocytemia: a Retrospective Analysis on 59 Patients.On Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Lydia Roy, MD, Jean Christophe Ianotto, MD, Joelle Guilhot, MBci, Emmanuel Raffoux, MD, Emmanuel Gyan, MD, PhD, Benoit de Renzis, MD, Laurence Legros, MD, Jean-François Viallard, MD-PhD, Françoise Boyer, MD, Cony Makhoul, MD, Franck E Nicolini, MD, PhD, Jean Gunecht, MD, Stephane Giraudier, MD-PhD

Blood (2010) 116 (21): 1974.

https://doi.org/10.1182/blood.V116.21.1974.1974

Published: 2010

Journal Articles

Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study

Blood (2010) 116 (21): 440.

https://doi.org/10.1182/blood.V116.21.440.440

Published: 2010

Journal Articles

A Phase II Study of Decitabine In Advanced Chronic Myelomonocytic Leukemia (CMML)

Blood (2010) 116 (21): 1873.

https://doi.org/10.1182/blood.V116.21.1873.1873

Published: 2010

Journal Articles

AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)

Jehane Fadlallah, Cecile Bally, Bruno Quesnel, Norbert Vey, Francois Dreyfus, Pascal Turlure, Stephane de Botton, Caroline Dartigeas, Benoit de Renzis, Sylvain Thepot, Raphael Itzykson, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2010) 116 (21): 2911.

https://doi.org/10.1182/blood.V116.21.2911.2911

Published: 2010

NARROW

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM)

Long Term Efficacy and Tolerance of Pegylated Interferon Alpha Therapy for Patients with High Risk Essential Thrombocythemia: An Observational Study of the French Intergroup of Myeloproliferative Disorders (FIM)

A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM)

Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial

Pegylated Interferon Alpha-2a Therapy for Patients with High Risk Essential Thrombocytemia: a Retrospective Analysis on 59 Patients.On Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study

A Phase II Study of Decitabine In Advanced Chronic Myelomonocytic Leukemia (CMML)

AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only